Case Report
Vemurafenib Response in 2 Patients With Posttransplant Refractory BRAF V600E–Mutated Multiple Myeloma

https://doi.org/10.1016/j.clml.2014.06.004Get rights and content

Introduction

BRAF (v-raf murine sarcoma viral oncogene homolog B) V600E activating mutations have been observed in melanoma, non–small-cell lung cancer, colorectal carcinoma, and a wide variety of additional malignancies, yet only some of these diseases have been tested for responses to BRAF V600E–specific inhibitors.1, 2 BRAF V600E and other less potent activating BRAF alterations have also been described in multiple myeloma3; however, the clinical response to BRAF-targeted therapy for BRAF V600E–mutated multiple myeloma is largely unknown. This report presents 2 posttransplant/conventional therapy–resistant patients with multiple myeloma with BRAF V600E mutations that were identified by a clinical next-generation sequencing–based assay and were subsequently treated with vemurafenib.

Section snippets

Patient 1

A 65-year-old man presented with a 5-cm palpable skull lesion. Serum protein electrophoresis found a monoclonal immunoglobulin G (IgG) κ spike of 6 g/dL and 324 mg/dL of serum free κ light chains. Diagnostic workup for myeloma included a 24-hour urine collection (which found excretion of 5.2 g of κ light chain), a bone marrow biopsy (which found a diffuse infiltration with plasma cells notable for expression of CD56), normal metaphase cytogenetic analysis, and a normal myeloma fluorescence in

Discussion

Activating genomic alterations in the mitogen-activated protein kinase signaling pathway are the most frequent oncogenic driver mutations in multiple myeloma.3 Whereas mutations in NRAS (neuroblastoma RAS viral (v-ras) oncogene homolog) and KRAS (Kirsten rat sarcoma viral oncogene homolog) may occur in 40% to 50% of myeloma cases, BRAF mutations are less frequent, occurring in approximately 2% to 4% of primary myelomas,4 with the majority of these alterations consisting of BRAF V600E activating

Conclusion

Patients with BRAF V600E–mutated myeloma may have an unusually aggressive clinical course associated with prominent extramedullary disease and a short duration of response to standard therapies. Vemurafenib has clinical activity in this form of multiple myeloma.

Disclosure

J.C., D.M., P.J.S., G.A.P., J.S.R., V.A.M., and S.M.A. are employees of and have equity interest in Foundation Medicine Inc. J.S. and J.P.S. state that they have no conflicts of interest.

References (6)

There are more references available in the full text version of this article.

Cited by (41)

  • The Multiple Myeloma Drug Pipeline—2018: A Review of Small Molecules and Their Therapeutic Targets

    2018, Clinical Lymphoma, Myeloma and Leukemia
    Citation Excerpt :

    BRAF mutations are found in an estimated 3% to 6% of MM patients. After demonstration of vemurafenib's clinical activity as both a single agent112 and combined with the Mek inhibitor cobimetinib113 in MM case reports, the V600E/D/K inhibitor encorafenib has recently begun a phase II trial (ClinicalTrials.gov identifier, NCT02834364) with the Mek blocker binimetinib in MM. In addition to the Mek-Erk pathway, the PI3K-Akt (protein kinase B)-mTOR (mechanistic target of rapamycin) route, also operating downstream of Ras, has come under intense scrutiny in the search for druggable targets for RRMM.

  • Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach

    2017, Clinical Lymphoma, Myeloma and Leukemia
    Citation Excerpt :

    Because up to 7% of patients with MM harbor concurrent driver mutations in KRAS, NRAS, and BRAF,14 this has clinical implications. Note that one of the patients, mentioned before, developed SCCs after 4 months of treatment with verumafenib at a dosage of 960 mg per day.36 Inhibition of MEK with the selective oral inhibitor trametinib has been proposed to overcome the paradoxical activation of the MAPK pathway in BRAF-mutated tumors.41

View all citing articles on Scopus
View full text